Zr89 + PET Companion Trial

NCT05279027 | Completed Early Phase 1 DMC FDA Drug

• 1 other identifier: 09620
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine. This study is a companion study to the "LIMIT Melanoma Trial." Patients with melanoma who are potentially eligible for the LIMIT Melanoma Trial and have at least one site of measurable disease based on RECIST 1.1 are potentially eligible. Associations with progression-free survival (PFS) and overall survival (OS) will be tested.

Conditions

Melanoma (Skin)

Keywords

Positron Emission Tomography

Outcome Measures

Primary Outcomes (2)

• Zirconium Zr 89 Crefmirlimab Berdoxa uptake

  Zirconium Zr 89 Crefmirlimab Berdoxa measured uptake \*(by standard uptake value) on Baseline and post-Treatment PET/CT scans in tumor lesions and lymphoid organs.

  21 days

• Change in uptake post therapy

  Measurement of change in Zirconium Zr 89 Crefmirlimab Berdoxa uptake between Baseline and post-Treatment PET/CT scans in tumor lesions and lymphoid organs.

  21 days

Secondary Outcomes (2)

• Post therapy outcomes

  until the end of the study, usually about 3 years

• CD8+ TIL density in tumor

  2 months

Study Arms (1)

PET imaging

EXPERIMENTAL

This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.

Drug: Zirconium Zr 89 Crefmirlimab Berdoxa

Interventions

Zirconium Zr 89 Crefmirlimab Berdoxa DRUG

Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation

PET imaging

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients, at least 18 years of age
• History of histologically confirmed melanoma as assessed per medical record review.
• At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.
• Potentially eligible to participate in the LIMIT Melanoma Trial.
• Patients must have adequate baseline organ function as determined per LIMIT Melanoma Trial (IRB 835033) (these tests will be completed as part of LIMIT trial screening and will not be repeated for the imaging companion study)
• Adequate organ function: per LIMIT Melanoma Trial (IRB 35033)
• System Laboratory Values Hematologic Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L Hemoglobin ≥ 9 g/dL Platelet Count ≥ 100 x 109/L PT/INRa and PTT ≤ 1.3 x ULN Hepatic Total Bilirubinb ≤ 1.5 x ULN AST and ALT ≤ 2.5 x ULN Renal Serum Creatinine ≤ 1.5 mg/dL Abbreviations: ALT = alanine transaminase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; INR = international normalized ratio; LLN = lower limit of normal; PT = prothrombin time; PTT = partial thromboplastin time; ULN = upper limit of normal.
• a Subjects receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to enrollment.
• b Subjects with known Gilbert's syndrome must have a total bilirubin \< 3.0 x ULN).
• c If serum creatinine is \> 1.5 mg/dL, calculate creatinine clearance using standard Cockcroft-Gault formula. Creatinine clearance must be ≥ 50 mL/min to be eligible.
• Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

You may not qualify if:

• Females who report they are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test prior to infusion of the study radiotracer to confirm they are not pregnant.
• Patients who have any splenic disorders, or had splenectomy, that in the opinion of an investigator could compromise protocol objectives.
• Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
• Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
• Ineligible for the LIMIT Melanoma Trial.

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead
• ImaginAb, Inc.: collaborator

Study Sites (1)

Perleman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Melanoma

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 8, 2022
• First Posted: March 15, 2022
• Study Start: March 8, 2022
• Primary Completion: May 6, 2025
• Study Completion: May 6, 2025
• Last Updated: September 19, 2025

Record last verified: 2025-09

Locations

US (1)